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Introduction
Detecting specific organ toxicity is critical
to toxicity testing. Current in vivo tests can
in fact do so, but these tests are expensive,
time consuming, and animal intensive. For
the past decade toxicologists have been
developing alternative in vitro tests for
assessing organ toxicity. Indeed, in vitro
tests have been developed that represent a
range ofanatomic structures from perfused
whole organs to subcellular fractions.
Table 1 details the various preparations
used to assess toxicity of the major organs
along with a listing of limitations and
advantages of the systems. Many of these
can be prepared from a variety of animals
including humans. Indeed many human
tissues are readily available, i.e., blood and
other fluids, liver, kidney, etc. When pos-
sible, human tissue experiments should be
given highest priority.
The most physiological organ prepara-
tion for toxicity studies is the isolated per-
fused organ. This system maintains tissue
architecture that allows for cell-cell inter-
actions and measurement of organ secre-
tory/excretory activity. However, the main
disadvantages are that it does not reduce
the number of animals used and there is
significant variability between animals.
The next level of tissue organization
available for toxicity testing is tissue slices.
These have been successfully prepared
from liver, heart, kidney, and brain, to
name a few. Although tissue architecture is
maintained, cell preservation is problem-
atic. Isolated suspended cell preparations
are used for blood cells, including cells of
the immune system. This works well for
short-term studies.
The first part ofthis report updates the
current status of organotypic cultures for
the major target organs of toxic agents.
This includes liver, kidney, neural tissue,
the hematopoietic system, the immune
system, reproductive organs, and the
endocrine system. The second part reviews
the application of in vitro culture systems
to organ-specific toxicity and evaluates
future prospects.
Current Methodsfor
Organotypic Cultures
Liver
In vitro models ofliver toxicity are detailed
by Guillozo (1). The liver is a major target
organ for toxic compounds. Hepatotoxicity
can be predictable or can be idiosyncratic
Environmental Health Perspectives - Vol 106, Supplement 2 * April 1998 427SPIELMANN ETAL.
Table 1.Advantages and limitations of in vitropreparations.
Model Advantages Limitations
Isolated perfused organ
(liver, heart, lung,
kidney, spleen, gonad)
Tissue slices, 0.25 mma
(liver, heart, lung, kidney,
skeletal muscle, brain, etc.)
Isolated suspended cellsab
Primary cell cultures and
early subculturesa.b.c
Cell linesac
Subcellular fractions
S9 fraction
Microsomes
Mitochondria
Vesicles ofdifferent plasma
membrane domains
Genetically engineered cells
(yeast, bacteria, insect
cells, mammalian cells)
Three-dimensional architecture preserved
Cell-cell interactions preserved (between
all resident cell types)
Histological examination possible
No influence of higher order systems
(humoral, endocrine, nervous, etc.)
Only in vitromodel for secretory/excretory collection
Maintenance of epithelial vascular interactions
Tissue architecture preserved
Cell-cell interactions preserved
Histological examination possible
Human material available for some organs
(liver, lung, kidney, brain)
Studies on several chemicals at different concentrations possible
Interspecies comparison possible
Various types from various tissues available, forexample, free cells
(blood cells) orfreshly isolated cells (e.g., immune cells)
Usually the cells retain tissue-specific characteristics
(receptors, metabolism)
Studies of several chemicals at different concentrations possible
Cryopreservation
Interspecies and interindividual comparison possible
Survival: at least a few days or a few passages
Retainment of differentiated functions under
appropriate culture conditions
Several chemicals can be tested at different concentrations
Interspecies and interindividual variability can be assessed
Coculture possible with other cell types (generation of
extracellular matrix, improvement of differentiation)
Induction studies possible (transcription/translation)
Permits three-dimensional cultures (spheroids, tubules, cysts)
Immortalization of primary cells (e.g., with SV40, papilloma virus)
Unlimited number of cells can be obtained
Appropriate for only some specific mechanistic studies
Interspecies studies are limited
Genetic engineering, namely, transfection of defined genes possible
(e.g., P450, transport proteins, receptors)
Cryopreservation
Drug-metabolizing enzyme activities preserved
Interspecies studies possible
Interspecies studies possible
Covalent binding studies
Drug-metabolizing enzyme activities preserved
ATP synthesis
P-Oxidation offattyacids
Oxidative phosphorylation
Receptor and transport studies
Express one or more human genes (CYPs, GST in development)
Could replace S9 or liver microsomes in the Ames test
Potentially many genes can betransfected stably
Unlimited number oftransfected cells
Loss of organ functions [loss of interactions between
distinct organs, including metabolic activation (except liver)
cytokine interaction and endocrine regulation]
Short-term studies (2-4 hr maximum)
Demanding experimental technology (temperature,
perfusate, oxygenation)
One organ per experiment (animal consuming)
Limited amount of compound and concentrations can be
tested per experiment
Human organs normally notavailable
All models are hypoxic if perfused (erythrocyte-
polymerized hemoglobin)
Standardization difficult (high-cost equipment
and consumables)
Only available for short-term studies (from a few hours
to2-3 days)
Not all the cells in slices, dependent on function, cell types,
and location within the section
Further loss of organ functions (secretory/excretory functions)
Isolation method notfor all tissues and not standardized
Onlyfor short-term studies (few hours)
Further loss of organ functions (loss of polarity and
intercellular signaling for certain cell types)
Further loss of organ function (phenotypic changes and
rapid loss ofthe mostdifferentiated functions)
Unstable phenotype
Some functions cannot be analyzed (e.g., bile
excretion in liver primary cultures)
No match to in vivocorrespondents due to loss of
specific functions (enzymes, transport proteins, receptors)
Unstable genotype
Further loss of cell function (unstable genotype and loss of
specific functions, resistant to anticancer drug toxicity)
Short-term studies (30-60 min)
Loss of receptor proteins
Cytosolic enzymes missing
Short-term studies (30-60 min)
Technically demanding
Short-term studies
Often cannot be recovered from cultured cells
Loss ofglycolipid anchored proteins
Currently still underdevelopment
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because of infrequent metabolic or
immunologic pathways within an exposed
population (2). The liver contains a variety
ofcell types, induding hepatocytes, Kupffer
cells, and ductal cells. Hepatocytes represent
two-thirds of the total hepatic cell popula-
tion and show a heterogeneous intralobular
distribution ofdrug-metabolizing enzymes;
these are more abundant in perivenous cells.
The liver is richly endowed with phase 1
and phase 2 enzymes, mostly located in
hepatocytes, with less activity in bile duct
cells and some perhaps in Kupffer cells (3).
More than 1000 chemicals are potentially
hepatotoxic, and some of these require
bioactivation by liver enzymes to become
hepatotoxic. The liver can also produce
metabolites that will be toxic for other
organs or tissues. Various factors can modu-
late enzyme activities, e.g., age, gender, dis-
eases, previous drug exposure, nutritional
status, and genetic polymorphism. Species
differences exist in drug-metabolizing
enzymes, particularly between humans and
laboratory animals, making extrapolation of
animal data to humans imprecise (1-3).
Liver tissue and cells can be studied ex
vivo in a variety ofways, each with specific
advantages and limitations: isolated per-
fused organ, tissue slices, suspended cells,
primary cultures, cell lines, subcellular frac-
tions, and genetically engineered cells
(Table 2) (1).
Because the isolated organ model is
difficult to handle and cannot be used for
human studies, tissue slices and isolated
hepatocytes, either in suspension or in pri-
mary culture, are currently the most pow-
erful models (4,5). They reflect the in vivo
situation, at least for a few hours, and can
be obtained from various species including
humans and fish (1,2).
Hepatocyte survival and function in
primaryculture depend on adequate cell cul-
ture conditions, and they can also be stimu-
lated to divide 1 to 2 times. Hepatocytes can
be cocultured with other nonparenchymal
cells: forexample, with Kupffer cells to study
the effects ofcytokines or with stellate cells
to study fibrogenesis. Hepatocytes cocul-
tured with primitive biliary cells represent
the most powerful model for long-term
survival and function of hepatocytes
(6-10). However, it must be underscored
that no culture condition can maintain
fully differentiated hepatocytes (some
drug-metabolizing enzymes arerapidlylost,
even if they remain inducible), and no
hepatic cell line expresses the large spectrum
ofliverfimctions.
Human cytochromes P450 (CYP) can
be expressed over short periods of time in
several genetically engineered cells (yeast,
bacteria, insect cells, mammalian cells).
Liver S9 preparations and microsomes are
used for the Ames test and oxidative
metabolism studies. Finally, nonparenchy-
mal cells can be isolated and cultured, e.g.,
Kupffer, endothelial, stellate, and bile duct
cells (1,2,9,10).
Kidney
The kidney plays a central role in mainte-
nance ofbody homeostasis, namely, water
and electrolyte balance. Many aspects of
renal structure and function render the
organ especially susceptible to toxic xeno-
biotics. These include the high rate of
Table 2. Advantages and limitations of in vitroliver preparations.
Model Advantages Limitations
Isolated perfused liver Functions close tothose ofthe in vivoorgan Short-term viability(2-3 hr)
(all enzyme equipment preserved) Studyofone compound only
Lobular structure preserved Bile excretion decreased after 1-3 hr
Functional bile canaliculi No study on human liver
Collection of bile possible Suitable onlyfor liverofsmall animals
Short-term kinetic studies (extraction)
Liver slices Lobular structure preserved (all enzyme equipment preserved) Viability: 6 hr-2 days
Selective intralobular effects detectable No collection of bile possible
Studies on human liverpossible Notall the cells preserved similary(interassayvariability)
Studies on several compounds atdifferent concentrations
Isolated hepatocytesa Obtained from whole livers orwedge biopsies Short-term viability(2-4 hr)
Functions closetothose of in vivohepatocytes No bile canaliculus
Studies on several compounds atdifferent concentrations
Cryopreservation
Interspecies studies
Representative ofthe different lobularsubpopulations
Primary hepatocyte culturesa Functions expressed forseveral days in certain conditions Earlyphenotypicchanges
Induction/inhibition ofdrug-metabolizing enzymes Altered bile canaliculi
Interspecies studies
Liver cell lines Unlimited cell number Variousdrug enzyme activities lost ordecreased
Some functions preserved Genotype instability
Subcellular fractions
S9000 xgfraction Drug enzyme activities preserved Short-term studies
Microsomes Drug enzyme activities preserved Short-term studies
Production of metabolites for structural analysis No cytosolic phase 2 enzyme reactions
Cofactors required foractivity
Mitochondria ATP synthesis Short-term studies
,-oxidation offatty acids Cofactors required foractivity
Oxidative phosphorylation
Genetically engineered cells One or more human enzymes expressed Useforspecific purposes only
Available onlyfor CYPs No physiologic levels of enzymes
Unlimited cell number
aOther cell types can also be isolated, cultured, and even cocultured with hepatocytes: forexample, Kupffer, endothelial, stellate, and bile ductcells.
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blood flow, the well-developed transport
systems for solutes and ions, the capability
to recover water and thereby concentrate
the solutes to be excreted, and the depen-
dency ofviability upon high mitochondrial
output. These tasks are confined to the
epithelial cells resembling the renal func-
tional units, the nephrons, which amount
to 70 to 80% oftotal renal mass. A number
of biochemical properties confined to
epithelial cells are related to enzymes that
maybioactivate drugs and otherxenobiotics
to become toxins. Activity ofthese enzymes
is influenced by a number of factors (dis-
ease, drug, exposure, age). In addition
immunoallergic mechanisms frequently
induce renal toxicity. Considerable inter-
species differences exist with respect to the
induction oftoxic nephropathies.
The isolated perfused (rat) kidney is
most appropriate for studying potentially
nephrotoxic xenobiotics when tubulovas-
cular integrity is required (11). The advan-
tage of the system is that no extrarenal
regulatory influences (hormones, blood-
borne factors) interfere in the study. This
model enables precise control of the con-
centrations of compounds being studied.
Because ofits sophistication, it is, however,
not suitable for routine application. It is an
animal-consuming experimental system.
The isolated perfused nephron is not
suitable for routine investigations, but this
system provides data on enzyme localiza-
tion and receptor distribution, which can
be used for confirming the site oforigin of
isolated cells (12).
Renal slices have been used extensively
in the past for renal transport and toxicity
studies, typically for no more than a 2-hr
period (13). Recently, precision-cut slices
have been used. They are easy to produce,
and commercial availability of slicers has
helped to minimize interlaboratory variabil-
ity. An advantage ofslices is that they pro-
vide a multicellular system in which
three-dimensional structures, and therefore
cell-cell contacts, are preserved. Kidney-spe-
cific parameters are maintained and rapid
and simple interspecies comparisons can be
performed. Site-specific effects can be stud-
ied and several functional parameters can be
assessed. The major disadvantages are lim-
ited lifespan and their morphological, func-
tional, and biochemical heterogeneity.
Collapse of nephron lumina hampers ade-
quate transport studies. Slice surfaces always
represent aregion oftissue injury.
Isolated glomeruli and tubular frag-
ments can be found in dissociated renal tis-
sue fragments rich in proximal, distal, or
collecting duct portions, or intact, decapsu-
lated glomeruli. These fragments are viable
and can be used for short periods to assess
acute effects ofchemicals. They have played
a key role in showing that some nephrotox-
icants (e.g., mercuric chloride) adversely
effect glomeruli well before tubular damage
occurs. Isolated renal proximal and distal
tubular cells have been used extensively for
acute nephrotoxicity studies. As they retain
most of the characteristics seen in vivo,
they can be used to study mechanistic
aspects of toxicity at the cellular level and
to design strategies for cytoprotection.
They also may be used for in vitro-in vivo
extrapolation and interspecies comparison.
This model is hampered by the loss ofcell
viability, polarity, and junctional com-
plexes after a maximum of 6 hr. These
losses make the study of specific epithelial
functions impossible. Approaches for
establishing primary cultures of renal cells
have been described by several laboratories
(14). Because ofthe heterogeneity ofrenal
tissue zones and nephron segments, it is
essential to apply isolation procedures and
selective culture conditions appropriate for
cells of the nephron segment of interest.
This in vitro system retains a number of
the characteristics of renal cells in vivo.
They form well-polarized epithelial mono-
layers and may retain adequate function
over longer periods of time than in the
models outlined above. For successful
exploration of the effects ofchemicals, the
following requirements must be met: the
cells must a) be polarized and possess
intact junctional complexes, b) displayvec-
torial transport of water and solutes and
the appropriate uptake ofxenobiotics, and
c) express nephron cell-specific functions of
transport, metabolism, and response to
extracellular signals (e.g., hormones). Most
but not all ofthese criteria can be met dur-
ing the early phase of culture. However,
cells tend to lose differentiated in vivo
functions over time and may therefore not
be useful for studying toxic side effects over
prolonged periods. Inadequate culture con-
ditions may accelerate the loss of this dif-
ferentiated phenotype, but the use of
defined media may help to stabilize the
differentiated phenotype.
Continuous (immortalized) cell lines
have been derived from certain nephron seg-
ments (Table 3). They are not transformed
and have retained a number ofrenal epithe-
lial characteristics, although they do not ful-
fill all the criteria listed above. Permanent
cell lines keep their state of differentiation
and can be used for studies of specific
Table 3. Continuous renal epithelial cell lines.
Cell line Species Segmental origin ATCC No.
LLC-PK1 Pig Proximal tubule ATCC CRL
1392
OK Opossum Proximal tubule ATTC CRL
1840
JTC-12 Monkey Proximal tubule Not listed
MDCK Dog Distal tubule/ ATTC CCL
collecting duct 34
A6 Xenopus Distal tubule/ ATTC CCL
laevis collecting duct 102
ATCC, American Type Culture Collection.
nephrotoxic mechanisms over prolonged
periods up to several days orlonger.
NeuralTissue
Neurotoxicity can be defined as any
"adverse effect on the chemistry, structure
and function ofthe nervous system, during
development or at maturity, induced by
chemical or physical influences" (15).
Though controversy exists about the inter-
pretation of the word adverse and the sig-
nificance of reversible versus irreversible
changes, there is agreement that changes
such as neuropathy or axonopathy are defi-
nitely adverse neurotoxic effects. Standard
acute, subacute, subchronic, and chronic
toxicity studies are relevant to the assess-
ment ofpotential neurotoxicity, as they are
conducted at different dose levels, in differ-
ent animal species, and with different dura-
tions of exposure. Clinical observations
and morphological examinations from
these studies can readily reveal effects on
the nervous system. Specific neurotoxicity
testing is conducted when there are indica-
tions of neurotoxicity, or on the basis of
structure-activity or other considerations.
This includes a series ofobservations, mea-
surements, and neuropathological exami-
nations in laboratory animals (16-18).
Positive results in these Tier 2 studies
would provide the basis for further tests
that may include neurochemical or electro-
physiological experiments, and are aimed
at characterizing neurotoxic effects and
identifying possible mechanisms. Special
considerations, and additional testing,
should be given to organophosphorus com-
pounds (for their ability to cause delayed
neuropathy) and to developmental neuro-
toxicants. As in other areas of toxicology,
the desire to reduce the number ofanimals,
and the time and costs oftesting, has led to
exploration of the possible use of in vitro
approaches for neurotoxicity testing.
Several in vitro systems can be consid-
ered as alternative testing systems for
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neurotoxicity (19-22). In decreasing order
ofcomplexity these models include organ-
otypic explants, brain slices, reaggregate
cultures, primary cell preparations, and
established cell lines. Each model system
has advantages and disadvantages. For
example, all are derived from animals
(rats or chicken) with the exception of
cell lines and, in some occasions, primary
cultures. In some systems, for example,
organotypic explants or brain slices, the
cytoarchitecture ofthe nervous system or
certain neuronal circuitries or biochemi-
cal processes are preserved. On the other
hand, primary cultures or cell lines allow
the study of the effects of toxicants on
isolated cell types (e.g., neurons, astro-
cytes, oligodendrocytes). Cell lines are usu-
ally the simplest to manipulate, but present
the problem of being transformed, and
may potentially display altered responsive-
ness (e.g., resistance) to toxicants. Systems
that involve coculture ofcells are also avail-
able, such as cocultures of neurons and
astrocytes or oligodendrocytes, or astro-
cytes and endothelial cells, to mimic in
vitrothe blood-brain barrier (23).
Hematopoietic System
Leukocytes (granulocytes, monocytes,
lymphocytes), erythrocytes, and platelets
circulate in the blood where they perform
specialized functions essential in immunity,
oxygen delivery, and blood clotting. A
hematotoxicant is defined as an external
substance that causes a clinically significant
adverse effect on the level or function of
these cells (24-28). Decreased cell number
is known as cytopenia and increased cell
number cytosis. Blood cells are produced
by precursor cells called progenitors, which
are found in the bone marrow (and spleen
ofsome animals). In vivo, hematotoxicants
act by direct effects on blood cells or their
progenitors, or by indirect effects mediated
by humoral factors (24-28). The availabil-
ity ofrecombinant cytokines has stimulated
the development of in vitro assays for many
progenitor populations in the myeloid, ery-
throid, platelet, lymphoid, and stromal lin-
eages (26), and these progenitors have been
cocultured with hepatocytes or transgenic
cells to study bioactivation (e.g., via CYP)
of protoxicants (25). Clonogenic assay for
the neutrophil monocyte progenitor called
colony forming unit-granulocyte/macro-
phage (CFU-GM) has been most com-
monly applied by laboratories in academia,
industry, and government to the study of
hematotoxicants in several species, includ-
ing human (25-27), so SGOMSEC 13
focused on the evaluation ofdirect effects of
toxicants on hematopoietic progenitors (28).
Direct effects of toxicants on circulating
blood cells (e.g., hemolysis) have been rou-
tinely assessed ex vivoand are not covered in
detail in this workshop.
Immune System
In vitro models suitable for study of
immune system toxicity are detailed by
Karol (29,30). The immune system is a
multicellular, multiorgan complex that
includes the spleen, thymus, lymph nodes,
and tonsils, as well as lymphoid areas ofthe
gut and lung. The function ofthe immune
system is to protect against agents such as
bacteria, viruses, and particulates in the
external environment, as well as against the
internal development of "nonself' neo-
plasms. Dysfunction ofthe immune system
is recognized as either heightened immune
reactivity, as in hypersensitivity disease, or
reduced immune surveillance that is mani-
fested as reduced ability to combat infec-
tious agents or tumors. Lymphoid cells
from the blood, lymph nodes, and spleen,
and fixed immune cells from solid tissues
can all be isolated and studied ex vivo.
Some of these cells can proliferate in
response to added growth factors, whereas
others are terminally differentiated and
their specialized functions can be assessed.
Reproductive Organs
Reproduction is a continuous cycle, but for
the purpose oftoxicity testing it is divided
into pregnancy, including prenatal and
postnatal developmental toxicity, and the
remainder ofthe reproductive cycle in both
males and females when fertility may be
impaired. To evaluate the reproductive tox-
icity of chemicals to humans, investigators
conducted multi-generational studies in
laboratory animals to provide information
on the effects ofindustrial chemicals on all
aspects of the highly complex reproductive
cycle (31). In drug development, segment
studies are conducted covering important
phases ofpre- and postnatal development as
well as fertility (32). Because the complex-
ity ofthe reproductive cycle and because of
the lack of validated alternative tests for
most ofthe steps in the cycle, testing in liv-
ing animals is the only option currently
available for assessing the possible effects of
chemicals on reproduction.
To study fertility in vitro, methods for
culturing ovarian and testicular cells and
tissues both from laboratory animals and
humans are established. Moreover, in vitro
fertilization and embryo transfer, including
the production of transgenic animals, are
currently usedworldwide in laboratory ani-
mals, farm animals, and for most of the
techniques, also in humans. Therefore,
techniques to assess the viability of sperm
and oocytes to fertilize are in clinical use
for both animals and humans (33).
Ex vivo cultivation ofwhole embryos is
used to evaluate toxic effects on prenatal
development in mammals, including
humans. From fertilization to implantation,
mammalian and human embryos can rou-
tinely be cultured. For the common rodent
species, fairly simple whole-embryo culture
techniques have been developed that usu-
ally start at the primitive streak stage and
allow development to the most important
phases of organogenesis. The usual culture
period during which there is acceptable
progress in development is usually 24 hr or
less (34).
The development and differentiation of
the most important embryonic organs can
be studied in culture, for example, develop-
ment of the limbs, heart, teeth, thyroid
gland, central and peripheral neural tissue,
and closure of the palatel shelves. The
induction of embryonic tissues by other
tissues, including induction ofsomites, the
spinal cord and other organs, as well as
interactions among tissues and the effects
of growth factors and hormones, can be
studied in specially designed systems, for
example, transfilter systems (33,34).
Cells ofalmost all embryonic organs of
mammals and most vertebrates can be
maintained in primary culture. To study
the developmental potential of embryonic
cells of organs of specific interest, micro-
mass cultures and aggregation cultures have
proven to be very useful. Embryonic stem
(ES) cells, which have the potential to
differentiate into all tissues of the body,
from laboratory animals and also from
some farm animals, are routinely used to
produce transgenic animals. ES cells ofthe
mouse will differentiate under appropriate
conditions into differentiated, mature
cells, e.g., contracting cardiac cells (35).
Embryonal carcinoma cells and permanent
cell lines derived from embryonic organs of
various mammalian species have been used
in the past for many purposes. As theyhave
usually lost specific characteristics of the
organ from which they were derived, data
obtained with such cells should be inter-
preted with caution. Like cell lines used in
neurotoxicology, the malignant nature of
these cells may confer unusual mechanisms
oftoxicant resistance that are not present in
normal human tissues.
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In condusion, tissue culture systems to
study the maturation of both oocytes and
sperm, and also in vitro fertilization and
preimplantation development, are adequate
for toxicology studies. In vitro culture of
mammalian embryos after implantation can
only be studied for limited time periods.
Standardization and improvement ofculture
conditions is recommended. The differ-
entiation ofES cells is a promising area for
understanding normal differentiation of
undifferentiated pluripotent cells into highly
specified cells. Improvement and standard-
ization of ES cell culture conditions may
allow better understanding of the mecha-
nism of action of embryotoxic/teratogenic
agents (34,35).
EndocrineSystem
Environmental endocrine disruptors have
been defined as exogenous agents that
interfere in vivo with the production,
release, transport, metabolism, binding,
action or elimination ofnatural ligands in
the body responsible for the maintenance
ofhomeostasis and the regulation ofdevel-
opmental processes. Consequently, targets
within this system include behavior, syn-
thesis and metabolism (i.e., aromatase),
transport (i.e., sex hormone-binding glob-
ulin, transthyretin), steroid receptors (e.g.,
estrogen, androgen), and steroid-respon-
sive genes as well as membrane receptors.
It is conceivable that substances may be
found that disrupt any or all of the pro-
tein, peptide, or amino acid endocrine or
paracrine regulators.
Consequently, measurement of dys-
function ofthe endocrine system due to an
environmental agent is similar in magni-
tude and complexity to the assessment of
the nervous or immune systems, in that
the endocrine system can affect the func-
tion and activity of multiple organs and
cells at numerous sites and is under the
constant control of feedback mechanisms.
Thus, it is impossible to conceive that a
single assay will be able to assess all ofthe
potential interactions that may lead to
endocrine disruption.
Currently, there are few established
methods for the identification and assess-
ment of chemicals and complex mixtures
that elicit endocrine-disrupting activities.
However, a number of in vivo and in vitro
assays have been used to determine drug
efficacy, or in basic research, to elucidate
mechanisms ofaction. As a result, many of
these assays have been adopted to predict
the risk that endocrine disruptors pose to
human health. At this point, there are no
gold standard validated assays that have
been accepted for regulatory purposes.
Indeed, regulatory agencies as well as the
scientific community are struggling to
develop assays to screen for endocrine
disruptors. A number ofin vivoand in vitro
assays have been proposed; their advantages
and limitations have been recently reviewed
and a compendium ofexisting methods for
assessing the endocrine system has also been
compiled (36-38). These assays examine a
number of different end points and use a
variety ofspecies as well as mammalian cells
in culture and yeast. However, in each case,
there is a lack ofstandardized protocols and
data assessment criteria. Therefore there are
no established benchmarks or response
parameters to ensure that the assays are
performing optimally and to systemati-
cally compare the value of established or
emerging assays.
Current Use of Test Systems. The
identification and assessment of endocrine
disruptors is complex as the elicited effects
may be species-, ligand-, organ/tissue-,
cell-, and response-specific. Moreover, the
diversity ofend points and the complexity
of feedback mechanisms make a compre-
hensive assessment of the impact of an
endocrine disruptor on endocrine function
a difficult task. Therefore, to examine the
potential endocrine-disrupting activities of
a substance, a battery ofin vivoand in vitro
assays is needed.
Established in vivomethods for assessing
the endocrine-disrupting activities ofchemi-
cals and complex mixtures include many of
the parameters used in conventional repro-
duction/developmental studies. These stud-
ies are expensive and time consuming and
their use is limited. Consequently, the chal-
lenge is to identify those substances that
warrant such intensive investigation.
In vivo assays for endocrine disruptors
are seriously lacking and require develop-
ment. Vaginal cell cornification and effects
on uterine wet weight performed in
rodents are typically used to assess in vivo
estrogenic activity (37). A number of dif-
ferent protocols and species have been
used. These assays require standardized
operating procedures (SOPs) that specify
species, strain, age, and route of adminis-
tration of test compound as well as other
potential interventions (i.e., ovariectomy).
Although these assays are considered to be
the most established and accepted end
points for in vivoestrogenic responses, they
lack sensitivity and their appropriateness is
questionable as rodents do not express sex
hormone-binding globulin (SHBG) after
parturition (39). Short-term in vivo assays
for other endocrine disruptors (i.e., andro-
gens, goitrogens) are essentially nonexistent
and require intensive development.
In addition, endocrine disruptors may
also elicit effects that are not manifested at
the tissue or organ level. Consequently, it is
essential that their effects be investigated at
more sensitive end points such as at the
level ofgene expression. Assessment may be
further complicated by the tissue-specific
activities ofsome endocrine disruptors. For
example, tamoxifen, a therapeutic antiestro-
gen used in estrogen responder positive
breast cancer management, exhibits agonist
activity in bone and the uterus but anta-
gonist activity in mammary tissue. It
apparentlydoes not affect behavior.
Therefore, it is essential to measure a
number ofdifferent genes since the elicited
effects maybe ligand- and response-specific.
Gene expression can be accurately mea-
sured using sensitive and quantitative
reverse transcriptase-polymerase chain reac-
tion (RT-PCR) assays that can also provide
valuable datafor riskassessment purposes.
A number of in vitro assays, namely
competitive ligand binding, protein expres-
sion and enzyme activities, have also been
used to investigate alleged endocrine dis-
ruptors. As with in vivo assays, in vitro
assays also require the establishment of
SOPs. Although in vitro assays exhibit
greater sensitivity and selectivity and pro-
vide more information regarding potential
mechanisms of action ofendocrine disrup-
tors, their use is also limited. In vitro assays
possess minimal metabolic activity and can-
not account for potential pharmacody-
namic interactions. Moreover, because of
the complexityofthe endocrine system, it is
not feasible to establish one assay that
would be capable of predicting all of the
potential adverse in vivo responses that may
be elicited after exposure to an endocrine
disruptor. Therefore, the assessment of an
endocrine disruptor should include a bat-
tery of in vitro assays evaluating a number
ofdifferent endocrine endpoints.
EmergingMethods. Several in vivo and
in vitro methods are currently being devel-
oped that may assist in the identification
and assessment of chemicals and complex
mixtures that elicit endocrine-disrupting
activities. Many ofthese assays are mecha-
nistically based and take advantage of the
known mechanisms of action of steroid
hormones. However, these assays lack
SOPs and they require further develop-
ment to determine ifthey are predictive of
in vivo responses. Emerging in vitro assays
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include the use of hormone-responsive
mammalian cells and recombinant yeast
cells in cell proliferation and gene expres-
sion studies (38,40-42). In vivo quantita-
tive gene expression assays that use PCR
are being developed to investigate tissue-
and response-specific effects of endocrine
disruptors. Moreover, recombinant DNA
technology is also being used to construct
transgenic rodents that express SHBG fol-
lowing parturition and therefore more
accurately model pharmacodynamic inter-
actions that may occur in humans.
Researchers are also investigating the possi-
bility of combining in vitro and in vivo
assays such as the development of an in
vivo cell proliferation model. This assay
would involve the use ofhormone respon-
sive cells and athymic mice to assess the
ability ofan endocrine disruptor to mimic
sex steroid activity in inducing cell prolifer-
ation under in vivo conditions. Although
these developments will improve the assess-
ment of endocrine disruptors, additional
research is necessary as to how endocrine
disruptors impact other endocrine end
points such as peptide hormone secretion,
transport, metabolism, and activity.
Interacdons ofOrganSystems
Initial interaction of a chemical with the
body occurs via inhalation, ingestion, or
dermal contact. As a consequence, the pri-
mary organs involved are the lung, skin, and
gastrointestinal tract. Toxicants may cause
an effect at these initial sites ofcontact, or at
distant organs because oftransport, metabo-
lism, or mediators released from these sites,
as well as from the differential sensitivity of
various organs. Moreover, even though ini-
tial interaction may be at one site, effects
may be evident at multiple sites because of
interactions between various tissues, for
example, by hormones, cytokines, antibod-
ies, neural innervation, toxic metabolites,
and plasma regulatory proteins. Prominent
examples ofthese interactive systems include
the immune system, nervous system, and
endocrine system, each of which is com-
posed of numerous cell types and cell
processes allowing interaction with multiple
systems and resulting in homeostasis. In
these cases, it is obvious that an assay for
toxicity, whether toward a specific cell or
molecular target, toward only a specific cell
type or toward aspecific cell factor, may not
be able to predict toxicity to the entire organ
system. For example, lack ofeffect ofa toxi-
cant on T-cell function cannot be used to
indicate lack of toxicity to natural killer
(NK) cell regulation ofthe immune system.
Some chemicals are organ specific with
respect to their toxicities. For example, car-
bon tetrachloride is a liver toxicant,
whereas trichloroethylene is a specific renal
toxicant. However, even though a chemi-
cal displays apparent organ-specific toxic-
ity, it may have secondary effects on other
organs due to interactions between organ
systems. For example, kidney toxicity that
results in necrosis ofthe cortex may result
in hematotoxicity manifest as erythropoi-
etin (epo)-responsive anemia as a conse-
quence ofdecreased kidney output ofepo.
Xenobiotic-induced antibody production
(immunotoxicity) mayresult in kidney fail-
ure due to accumulation of antigen-anti-
body complexes in the renal glomeruli.
Cadmium-induced renal toxicity results in
production of antibodies to laminin that
bind to placental tissue. This results in
reduced uptake of methionine into the
fetus, leading to developmental toxicity
manifest as neural tube defects.
A further result of organ interactions is
the occurrence oforgan-specific toxicity due
to a secondary effect. Chemically induced
altered liver metabolism may result in
decreased serum levels of estradiol that
result in altered reproductive function. It is
apparent that design of in vitro assays must
consider organ system interactions. Because
ofsuch interactions, single isolated in vitro
assays may be insufficient for adequate
assay ofthe organ-toxic potential ofchemi-
cals. The replacement of systemic toxicol-
ogy by alternative assays has received little
scientific or regulatory attention.
In VitroOrgan Toxicity
Intoduction
Today in vitro methods are used predomi-
nantly to analyze the mechanism ofaction
of toxic agents. In a few exceptional cases,
as in acute local irritancy testing, they can
be used for classification and labeling of
chemicals without further testing in ani-
mals. The situation is less promising in
organotypic and systemic toxicity testing.
Because the application and acceptance of
in vitro alternatives in organ toxicity very
much depends on the specific problem to
be analyzed, established new organotypic
tests and their limitations will be described
separately for each of the organ systems
described in the previous section. An
overview ofestablished organotypic tests is
given in Table 4.
Current Applications ofin Vitro
LiverModels. In vitroliver models are cur-
rently used for metabolism, mechanistic,
and screening studies (Table 5); a few vali-
dation studies have been performed. These
are detailed byGuillouzo (1,2,9,10).
METABOLISM STUDIES. In vitro models
from different species including humans
are very useful and are widely used to get
information on kinetics, metabolic path-
ways, induction/inhibition effect, and
drug-drug interactions. There is a very
good qualitative correlation in metabolic
pathways between in vitro and in vivo data
(3). Data on human material are critical to
select the second species for toxicological
studies and to predict potential effects ofa
new drug in humans (9). Different in vitro
models can be used in parallel to get more
information on metabolism (i.e., hepato-
cytes or slices, microsomes and recombinant
CYPs) (1-3).
MECHANISTIC STUDIES. In vitro models
are currently used for investigating mecha-
nisms of toxicity, e.g., identification of a
toxic metabolite or analysis of cellular
lesions. They are not appropriate for iden-
tifying chemicals that will induce an
immunoallergic toxicity.
SCREENING. Primary hepatocytes are
used in the unscheduled DNA synthesis
(UDS) test; the S9 fraction or microsomes
from rat liver are used in the Ames test.
Because of their low proliferative capacity,
hepatocytes do not appear to be appropriate
for the micronucleus test or the sister chro-
matid exchange test. In vitro liver models
are also used for acute toxicity testing.
However, their advantage over nonhepatic
cells has not beenwell demonstrated.
REGULATORY. Only the Ames test and
the UDS test with rat liver preparations are
accepted in regulatory guidelines. National
and international validation studies have
been performed for acute toxicity. No posi-
tive conclusion has been drawn. Presently
no new prevalidation or validation study is
being run.
THE FUTURE USE OF IN VITRO LIVER
MODELS. The following models should be
developed since theyhold promise:
* cocultures of hepatocytes with other
nonhepatic cells
* immortalized cell lines expressing liver-
specific functions
* genetically engineered cells expressing
stable human phase 2 enzymes
Research to develop more sophisticated
liver models should consider the following
priorities:
* basic research to understand why drug-
metabolizing enzymes are lost but
remain inducible in vitro, whatever the
culture conditions
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Table 4. Established neworganotypic tests.
Reference Validation regulatory/
Organ Test End point Use method Acceptance Limitations Reference
Nervous system Cells NTE/AChE S/A OPIDN (hen) OECD only OnlyOps (7)
Nervous system In vitroBBB Multiple (funct/ Potential Only BBB
perm) S/A
Hematopoiesis CFU-GM Colonyformation A/R Primate ECVAM-PS Onlyneutropenia (25)
hematology
Endocrine Gene expression Luciferase reporter M/S - Low metabolic (36)
MCF7 gene activity
Endocrine Yeast gene ,B-galactosidase M/S Low metabolic (40)
expression activity
Kidney Epithelial barrier Transepithelial M/S Prevalidation Onlyepithelial (36)
function tests electrical stage
resistance and
permeability
Immune system LLNA Skin sensitization S/R GP maximization ACC/Val Induction phase (43,44)
test ofsensitization
MEST Skin sensitization S/R GP maximization ACC/Val (44)
MEST test
SAR Skin, respiratory S/R Inhalation tests Dependent onquality (45)
sensitization ofdatabase
Embryo Cells (embryo, Differentiation S/M Segment 11 Undergoing Measures only one (34)
stem) morphology embryotoxicity validation phase ofdevelopment
Abbreviations: M, mechanistic; S, screening; A, adjunct; R, regulatory, exposure limits; BBB, blood-brain barrier; NTE; neurotoxic estrase; AChE, acetylcholinesterase; OPIDN,
organophosphate induced delayed neurotoxicity; Ops, organophosphates; funct/perm, function/permeability; ECVAM-PS, ECVAM prevalidation study; GP, guinea pig;
ACC/VAL, accepted/validated; MEST, mouse ear-swelling test.
Table 5.Applications of human and animal in vitroliver preparations in pharmacotoxicological studies.a
Suspended Cultured
Assay Slices hepatocytes hepatocytes Microsomes
Metabolic profile + + +
Comparative interspecies + + +
metabolism
Kinetic studies + + + +
Drug-drug interactions + + + +
Induction studies +b +
Inhibition studies + + + +
Toxicity screening + + -c
Mechanistic studies + +b +
UDS test + + +
UDS, unscheduled DNA synthesis. + possible; +, currently used; -, not suitable. aIsolated organs not included
because of the lack of availability of human liver. bShort-term study. cCan be used instead of the S9000xg
supernatant in the Ames test.
* development of in vitro models of
immunoallergic toxicity (e.g., identifi-
cation ofnewantigens)
When establishing in vitro liver models
in toxicitytesting, thefollowing toxicological
end points should be considered:
* acute nonspecific toxicity using non-
hepatic cells
* toxicity in liver cells with at least two
time points-acute and after a few days
ofexposure (to mimic chronic toxicity)
* toxicity on hepatocytes cocultured with
nonhepatic target cells (e.g., kidney
cells). Are metabolites formed by the
liver toxic for other cells?
Cocultures of hepatocytes with other
target cells should be developed and
evaluated/validated under static culture
conditions and under perfusion culture
conditions.
New developments that will lead to a
wider acceptance of complex liver and/or
metabolising in vitromodels include:
* new applications of recombinant
human CYPs
* replacing the rat liver S9 from micro-
somes by genetically engineered cells
expressing human CYPs in appropriate
concentrations in the Ames test. It
should be possible to mimic the human
liver situation including genetic defects
in some CYPs
* replacing hepatocytes in cocultures with
nonhepatic target cells. It should be
emphasized that human liver and human
CYP450 is the gold standard. Human
material has to be better standardized
(functional activities, free of virus).
However, ethical standards for using
human tissue must be established and
harmonized at the international level.
Kidney. Morphological end points
are used to quantify nephrotoxicity, and
light microscopy is widely used to assess
cellular changes. The isolated perfused
kidney, slices, and tubular fragments can
be fixed and processed for routine
histopathology or for immunochemical or
histochemical investigations and quantita-
tively evaluated. Light microscopy is espe-
cially appropriate for monitoring changes
in cultured epithelial monolayers. Growth
and dynamic changes can easily be assessed
by videoimaging techniques. If cells are
grown on solid supports (glass or plastic)
the number ofdomes (indicative ofvector-
ial transport activity) may be quantified
and changes in monolayer integrity can
be delineated.
None of the in vitro systems described
above has reached a level ofstandardization
or validation acceptable to regulatory
authorities. A number of test procedures
applied in mechanistic studies of nephro-
toxicity are outlined in Table 6.
An important parameter for evaluat-
ing nephrotoxicity of a chemical is the
measurement of epithelial leakiness with
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Table 6. Functional end points used in in vitronephrotoxicity assays.
End points Applicability Comments
Cell viability
Dye exclusion/retention Renal cortical slices Applicable in intact cell systems
Enzyme/ion leakage Renal fragments and slices (for example K+content)
Isolated cells (in suspension) Enzyme leakage provides
Primary cell cultures information on regiospecificity
Cell lines NB:MTTassay is not specific
for mitochondrial damage
Synthesis of macromolecules
Protein Renal cortical slices Check uptake of precursors
DNA/RNA Renal fragments
Isolated cells
Primary cell cultures
Cell lines
Matrix elements May be useful in glomerular/
interstitial cell cultures
Rate of proliferation
(clonogenic assays) Cell lines Total protein measurements
(usually reflect cell number)
Carrier-mediated transport
Glucose Systems containing proximal Can be quantified by uptake
tubule cells ortransport
Isolated tubules (transepithelial
transport)
Organic ions Cultures on porous membranes Uptake applicable to all
transepithelial systems
Checkeffects of specific inhibitors
Check paracellulartransport
Notfor routine use
Inorganic ions Notwidely used
Low molecularweight proteins
Endocytosis of labeled proteins
orcarbohydrates
Cultured cells ofproximal Usually used radiolabel or
tubular origin horseradish peroxidase
Easy in vivo/in vitrocomparison
Barrierfunction All epithelial systems, intact Assessment ofdiffusion of
epithelial, orconfluentcultures extracellular markers, or
on porous membranes electrophysiological measurements
MTT, methylthiazoldiphenyltetrazolium bromide.
indicator compounds, or the more sensitive
end point of transepithelial electrical resis-
tance generated by the vectorial transport
ofions. Epithelial leakiness has been shown
to be more sensitive than biochemical mea-
sures (enzyme leakage) for renal epithelial
cell injury (46).
In vitro systems are well suited for
studying interactions ofchemicals with cel-
lular structures. Initially the time- and
dose-response relation should be explored.
The next experiments should be conducted
at relevant, sublethal doses. In addition,
the concentrations used should be relevant
to those delivered to the kidney in vivo. It
is possible to elucidate toxic mechanisms
bystudying the following sequence:
* uptake (transport) of chemical or toxic
metabolite
* interaction at target site within the cell
(protein, DNA, lipid)
* check of cellular response in the fol-
lowing compartment: plasma mem-
brane (transport, signal transduction,
leakage), nucleus (gene expression,
nuclease activation, mutation), cyto-
plasm/cytoskeleton (glutathione deple-
tion, protein processing), lysosomes
(protein degradation), and mitochon-
dria (adenosine triphosphate [ATP] syn-
thesis, fueling of transport work). The
results obtained will indicate whether
lethal damage (necrosis, apoptosis),
repair, orproliferation occurs.
There are several improved assays for
nephrotoxicity under development. Organo-
typic cultures have recently been improved
by the combined use ofmicroporous growth
supports and application of the medium
under continuous flow (perfusion) (47).
The results to date show considerable
improvement in the differentiated state of
both primary cultures and cell lines at least
with respect to morphology. Thelife span of
primary cultures can be expanded up to
several weeks without evidence of the
marked changes in morphology indicative
ofdedifferentiation.
Neural Tissue. In vitro systems are
amenable and very useful for mechanistic
studies at the cellular and molecular level.
As such, they have been used extensively in
neurobiology and, to a minor extent, in
neurotoxicology. As one ofthe problems of
neurotoxicological research is the limited
knowledge of mechanisms of neurotoxic
damage, in vitro systems offer a useful way
to apply biochemical, morphological, mol-
ecular biology and imaging techniques to
the achievement ofthis goal (18,19).
When in vitro systems are considered as
screening tools for detecting putative neu-
rotoxicants, two important issues to be con-
sidered are the cell systems to be used and,
most importantly, the end points to be
measured (20,27). Suggested approaches
involve the use of a battery of cell types
such as a neuronal and a glial cell line, a
more complicated system, and a nonnerve
cell line. End points to be measured in
vitro should include indicators ofcytotoxi-
city, viability, as well as of neurotoxicity.
Comparisons between nerve and nonnerve
cells would offer indication of whether a
chemical may have differential effects or
display different potencies in these differ-
ent cell types. However, it would still be an
indication of cytotoxicity rather than neu-
rotoxicity. Several end points for neurotox-
icity have been proposed and many more
could be suggested; these include enzymes,
receptors, second messenger systems, ion
channels, etc. Because ofthe complexity of
the nervous system and the large number
of potential targets, the choice of end
points is crucial to avoid false positives and
false negatives.
HematopoieticSystem
The CFU-GM assay is the most frequently
used progenitor assay in toxicology
(24-28). It meets important prerequisites,
including ease of use and portability
between laboratories, low expense, high
interlaboratory reproducibility, and the
ability to assess toxicant effects on the
actual target cell in humans (25). At this
time, it is important to recognize that
CFU-GM data are most meaningful when
neutropenia is the likely in vivo toxicity
(26). The in vivo end point of toxicity to
be predicted with the CFU-GM assay is a
reduction in the number ofneutrophils in
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the blood. There is a relationship between
progenitor numbers and blood-cell counts
in vivo, so it should be possible to predict
the reduction in CFU-GM in vivo, and
thereby the decrease in neutrophil counts,
from the toxicant-dependent inhibition of
CFU-GM in vitro (35).
Currently, none of the in vitro
hematopoietic assays has been validated for
toxicological purposes, although an
European Centre for the Validation of
Alternative Methods (ECVAM)-supported
validation study will focus on the CFU-
GM assay for predicting the level of acute
exposure that causes severe neutropenia
(25). In clinical oncology, the IC90 end
point from the CFU-GM test is used for
comparative toxicology of an investiga-
tional antineoplastic agent in humans,
mice, rats, or dogs to determine if dose
adjustment is required and to derive phar-
macological targets for dose escalation
(26,28,48-50). In cases of extreme differ-
ences in hematotoxicity between species,
the CFU-GM assay could be used instead
ofhematology studies in primates. In phar-
maceutics, the CFU-GM assay has been
used to identify and halt the development
of antiviral nucleoside analogues that
would likely be myelosuppressive in
humans (27). This assay also could be use-
ful in guiding the development of antineo-
plastics that show activity against human
tumor xenografts primarily because they are
human-selective toxicants, rather than
tumor-selective agents (50). When viewed
as preclinical toxicology and used for early
decisions in drug development, comparative
CFU-GM toxicology could be a justifica-
tion to cancel a compound that will likely
cause unacceptable hematotoxicity clinically
andtherebyavoid useless animal toxicology.
In the near future, the CFU-GM assay
could be a useful adjunct to test number
407 of the Organisation of Economic
Co-operation and Development (OECD)
Guidelines for Testing of Chemicals (28-
day repeat-oral dose toxicology). The usual
species is rat, but other species are allowed,
and comparative in vitro toxicology in the
CFU-GM assay might suggest an alterna-
tive species that is closer than the rat to
human sensitivity. It could also find use as
an adjunct test when rat histopathology or
hematology (absolute neutrophil count)
indicate bone marrow toxicity, to deter-
mine if humans will be more or less sensi-
tive than the rat. As soon as an in vitro end
point is identified that predicts the hemato-
logic no observable adverse effect level
(NOAEL), the assays of hematopoietic
progenitors could prove useful for predict-
ing the acute permissible exposure limits for
human marrow of food contaminants and
additives, industrial chemicals and environ-
mental pollutants, and chronically adminis-
tered medications (15,16,18,33). For
prioritizing regulatory research on potential
human hematotoxicants, it could be helpful
to determine ifhuman CFU-GM is inhib-
ited at exposure levels that occur in the tis-
sue of exposed individuals which do not
lead to clinicallydetectable neutropenia.
Immune System. Most of the assays
used to detect immunotoxicity are per-
formed in conjunction with the standard
28-day rodent toxicity testing protocol of
Karol (51). However, in the United States,
mice, rather than rats, are more commonly
used in immunotoxicity testing (52,53).
Because of the complexity of the immune
system, a battery of tests is necessary to
assess immunosuppressive properties of
chemicals. Currently, a two-tier approach is
used, with each tier consisting ofat least five
assays (54). If positive results are obtained
in the first tier oftests, chemicals are evalu-
ated further in the second tier which
includes an assessment of suppression of
host resistance to either an infectious agent
or a transplantable tumor.
Correlations between test outcomes and
altered host defense have been studied to
reduce the dependence on multiple assays
and the use of large numbers of animals.
Limited results indicate that a combination
of three tests from the battery, each of
which assesses functional capacity of
immune system components or ofthe inte-
grated immune system, affords excellent
prediction ofimmunotoxicity (55). NK cell
activity, important in the immune protec-
tion of the host against neoplastic growths,
is assessed by an in vitro assay of NK cell-
mediated killing ofradiolabeled tumor cells.
Peripheral blood cells from chemically
dosed animals are the source of NK cells
(56). A second cellular assay is based on
analysis oflymphocyte surface antigens after
chemical exposure (57). The third compo-
nent ofthe testing triad is either assessment
of delayed-type hypersensitivity, or the
plaque-forming assay. Both tests assess the
integrated function ofvarious segments of
the immune system that include T and B
lymphocytes and macrophages (or other
antigen-presenting cells) (58). It is antici-
pated that results obtained from this assay
triad will be sufficient for regulatory deci-
sions. This development would lead to a
substantial reduction in the number ofani-
mals used forimmunotoxicity screening.
Hypersensitivity is an adverse immuno-
logic response, most typically occurring in
the skin and lung, that causes tissue distur-
bance, disruption, or death (59). At least
two exposures to the causative agent are
necessary to effect a response: the first
exposure primes the system to respond, the
second and additional exposures elicit the
reaction. Current regulatory guidelines
require animal testing to assess the skin
sensitization potential ofchemicals (44).
Although the mechanisms of skin and
respiratory hypersensitivity have not been
fully elucidated, several steps in the initia-
tion phase of the process are understood.
For dermal sensitization the process is initi-
ated by penetration of the agent through
the epithelial barrier, followed by interac-
tion with a carrier molecule. Simple mech-
anistic tests have been developed to address
this phase of the process (60). One test,
the local lymph node assay (LLNA), uses
mice and examines the ability ofchemicals
to stimulate proliferation of lymph node
cells (43). The test has undergone a valida-
tion trial and has been accepted by OECD
for regulatory use. Another method well
suited to assessment ofsensitization poten-
tial of chemicals uses structure-activity
relationships (SAR) (45). Several SAR
models have been described for dermal sen-
sitization and typically incorporate a para-
meter to estimate penetration of the skin
(usually log P), and a reactivity parameter
(dipole moment). Such models have been
found to have a sensitivity and specificity
approaching 90%.
SAR is also being developed to esti-
mate the hypersensitivity ofpotential res-
piratory allergens. Preliminary validation
ofthis methodology indicates a sensitivity
of 86% and specificity of 95%. Other
mechanistic methods are being applied to
predict respiratory hypersensitivity. As
IgE antibody has been implicated as con-
tributing to the mechanism of some
chemical respiratory allergies, assessment
of the concentration of IgE in serum has
been proposed as a screen for chemical
respiratory allergy. The test is performed
in mice and awaits validation studies with
both positive and negative chemicals
(43,45).
Other mechanistic assays used to
estimate the potential ofa chemical to elicit
respiratory hypersensitivity include the
basophil histamine release assay and cellular
production ofcytokines (59,61). Histamine
is known to contribute to the airway con-
striction that typifies allergic airwaysensitiv-
ity and cytokines are proinflammatory
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mediators released from numerous immune
cells. These assays are typically conducted in
rodent species. Measurement ofcytokines in
serum or bronchial lavage and release of
cytokines from bronchoalveolar cells also
have been done in humans. These tests mea-
sure one end point of hypersensitivity and
should be used in conjunction with other
assays to better assess the allergic potential of
a chemical.
Reproductive Toxicology. All of the
established in vitro methods are currently
used to study adverse effects of chemicals
and physical agents on fertility and devel-
opment in mammals. Special problems can
be assessed on human material, e.g., trans-
fer of chemicals into tubular and uterine
fluid as well as into sperm and seminal
fluid. These methods have been used as
adjunct tests to the current long-term in
vivo studies in rodents both for the safety
assessment ofdrugs and for risk assessment
ofexisting chemicals (34).
Whole embryo culture systems have
been established in industry for screening
purposes and mechanistic studies. Because
the test is difficult to standardize, it has
been used succcessfully in only a few labo-
ratories. The whole embryo culture assay
underwent several standardization and vali-
dation trials in Europe (63). For a given
group ofstructurally related chemicals, the
whole embryo culture assay can be used in-
house for screening purposes. Limb bud
cultures, brain cell aggregates, cultures of
palatal shelves, embryonic lung, and many
other organs both from rodents and even
human tissues, and organs from aborted
fetuses have been used extensively for
mechanistic studies as adjunct tests to
standard embryotoxicity tests in rodents
(33,34). None ofthese assays has been estab-
lished in industry or contract laboratories for
screening purposes.
In vitro embryotoxicity tests using
permanent embryonic cell lines failed to
show any correlation to in vivo data in a
validation trial conducted in the United
States in 1988. Such assays are therefore
not even used for in-house screening pur-
poses in industry laboratories. The use of
ES cells for in vitro embryotoxicity testing
(35) is currently undergoing a validation
trial sponsored by ECVAM. This assay is
not yet established in industry.
The micromass assay using limb and
brain cells is established in industry. It
underwent some validation and can be used
as an internal screening assay to classify
chemicals within a given class by high or
low embryotoxic potential. This has been
shown by Flint (64) for fungicides and by
Kistler for retinoids (65). A standardized
protocol micromass assay was tested in an
international validation trial, and Flint
reported in 1993 that this assay correctly
identified chemicals that are known to be
teratogenic both in humans and the most
common rodent species. These data have
not been published. A validation trial ofthe
micromass assay in the Netherlands was less
successful, therefore the micromass assay has
become less popular, even though it had
been established in both industry and
contract testing facilities.
Avalidation trial that examined both the
whole embryo culture assay and micromass
assay showed that the predictive value is
considerably improved when the two assays
are combined (66). Since the two tests
require special equipment and a trained
staff, they are established only in contract
testing facilities. None of the in vitro tests
established in the area of reproduction and
fertility has been standardized, validated, or
accepted for regulatory purposes.
Endocrine System. Currently available
in vivo and in vitro methods used to iden-
tify endocrine disruptors and to assess the
risk they pose to human and wildlife health
are limited, lack sensitivity, and do not
adequately account for all potential adverse
effects. More specifically, it has been sug-
gested that in vitro assays are not predictive
of adverse in vivo effects and may provide
false negative results due to their minimal
metabolic ability, a factor necessary in the
bioactivation of alleged endocrine disrup-
tors. Therefore, new in vivo and in vitro
methods are required that are complemen-
tary and assess the effect of endocrine dis-
ruptors on a number ofdifferent endocrine
end points. In vitro methods, which gener-
ally have greater sensitivity, can be used to
identify and prioritize substances that
require further in vivo investigation as well
as to provide information on potential
mechanisms of action. The development of
new in vivo assays are necessary to provide
methods to evaluate the impact ofendocrine
disruptors on a number of different
endocrine end points. The use of comple-
mentary in vivoand in vitro assays ensures a
comprehensive assessment ofthe endocrine-
disrupting activities of a substance or
complex mixture.
USE OF ALTERNATIVE METHODS. It is
suggested that a battery of in vitro and in
vivo assays can be used in a tiered strategy
to identify and assess the potency ofalleged
endocrine disruptors. In vitro assays could
be used as an initial screen to identify
endocrine-disrupting chemicals and com-
plex mixtures. Results from these studies
would prioritize chemicals that warrant
further in vivo assessment and provide use-
ful data for SARs that could also be devel-
oped to identify potential endocrine
disruptors. The effect of alleged endocrine
disruptors in vivo could then be investi-
gatedwith attention directed to specific end
points based on data obtained from in vitro
assays. This strategy ensures that the most
likely in vivo targets are assessed as
endocrine disruption must be demonstrated
in an in vivomodel.
Future Prospects
Despite the rapid progress in cell and tissue
culture techniques described in this paper,
new methods provide only a limited
amount ofthe information that is essential
for the safety assessment of chemicals and
that can sufficiently be obtained from test-
ing in animals. Although significant
progress has been made, in the near future
in vitro tests will not allow evaluation of
systemic and long-term effects of exposure
to drugs and hazardous chemicals.
In contrast, in vitro methods are
routinely used in mechanistic studies on
the effects of toxic chemicals at the cellu-
lar and molecular level. Thus, mechanistic
in vitro studies can be used as adjuncts to
toxicity testing in animals and offer new
prospects to risk assessment. The results
of in vitro studies on human cells and
tissues are essential to evaluate if toxic
effects observed in animals are likely to
occur in man.
Although most of the contributors to
this document are experts in only one or
two areas oftoxicology, there was consen-
sus that human cells, tissues, and organs
should be the gold standard in organ-
specific in vitro toxicology. All members
ofthe group felt that research in this field
should concentrate on improving culture
techniques that will allow better preserva-
tion of human material. To make better
use of in vitro organ and tissue cultures in
the risk assessment process, access to
high-quality human material will be
essential. This may, however, raise ethical
considerations that must be solved at the
political level.
Recommendations
* Improve the infrastructure for alterna-
tive toxicity testing through the follow-
ing actions: a) establish mechanisms to
increase the availability, distribution,
and use of human tissue and cells for
Environmental Health Perspectives * Vol 106, Supplement 2 * April 1998 437SPIELMANN ETAL.
alternative toxicology testing; b) develop
and make available relevant reference
compounds for toxicity assessment in
each organ system; c) organize and
make available via the Internet com-
plete in vivo toxicology data, including
human data, that contain dose, end
points, and toxicokinetics whenever
available; and d) establish mechanisms to
assure that biological material, reference
chemicals, and data are subject to inter-
national standards for quality control
and assurance.
* Identify and validate biological end
points for target organ toxicity that can
be reliably used in developing alternative
strategies.
* Develop methodology to predict the
target organ oftoxicity using alternative
methods.
* Develop procedures to assure early
standardization ofalternative tests.
* Minimize the number of in vitro tests
by using the most predictive ones.
* Develop alternative methodology for
detection of toxicity due to multiple
organ interactions.
* SARs and computational models
should be given a high priority for
development and validation as alterna-
tive approaches toward reduction of
animal testing.
* Develop, standardize, and validate co-
culture models involving bioactivating
cells, tissues, and subcellular fractions
with other target cells in static and
perfused systems.
* Complete the development ofthe bat-
tery of transgenic cells that express the
range ofhuman CYPs and thereby serve
as an alternative to the presently used S9
microsomes derived from animals in
assessments predictive ofhuman risk.
* Evaluate the origin and suitability
ofcultured cell lines to assess particular
toxicants. For example, use tumor-
derived cell lines in alternative methods
only if they are derived from tumors
that are not resistant to cytotoxic
anticancer drugs.
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